Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2016
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus
Parvathi Ranganathan, Trinayan Kashyap, Xueyan Yu, et al.
Leukemia & Lymphoma
|
February 19, 2019
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics
Tzung-Huei Lai, Shaneice Mitchell, Pei-Jung Wu, et al.
Leukemia Research
|
September 3, 2013
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
Deepa Sampath, Asifa Malik, William Plunkett, et al.
Journal of Hematology & Oncology
|
February 25, 2021
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Timothy L Chen, Bonnie Harrington, Jean Truxall, et al.
Leukemia & Lymphoma
|
December 16, 2025
NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia
John R Sanchez, Chaomei Liu, Vishakha Pawar, et al.
American Journal of Hematology
|
May 14, 2022
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis
Hua-Jay J Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, et al.
Blood Advances
|
October 26, 2022
HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia
Tzung-Huei Lai, Hatice Gulcin Ozer, Pierluigi Gasparini, et al.
Blood Advances
|
April 29, 2022
Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy
Max Yano, Chia Sharpe, J Rachel Lance, et al.
Leukemia
|
August 8, 2020
Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations
Alice S Mims, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2017
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
Alessandro Canella, Alessandra M Welker, Ji Young Yoo, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2016
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus
Parvathi Ranganathan, Trinayan Kashyap, Xueyan Yu, et al.
Leukemia & Lymphoma
|
February 19, 2019
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics
Tzung-Huei Lai, Shaneice Mitchell, Pei-Jung Wu, et al.
Leukemia Research
|
September 3, 2013
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
Deepa Sampath, Asifa Malik, William Plunkett, et al.
Journal of Hematology & Oncology
|
February 25, 2021
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Timothy L Chen, Bonnie Harrington, Jean Truxall, et al.
Leukemia & Lymphoma
|
December 16, 2025
NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia
John R Sanchez, Chaomei Liu, Vishakha Pawar, et al.
American Journal of Hematology
|
May 14, 2022
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis
Hua-Jay J Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, et al.
Blood Advances
|
October 26, 2022
HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia
Tzung-Huei Lai, Hatice Gulcin Ozer, Pierluigi Gasparini, et al.
Blood Advances
|
April 29, 2022
Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy
Max Yano, Chia Sharpe, J Rachel Lance, et al.
Leukemia
|
August 8, 2020
Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations
Alice S Mims, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2017
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
Alessandro Canella, Alessandra M Welker, Ji Young Yoo, et al.
Page
of 6